Contact UsQuotation
Shopping Cart
Remove All
  • TargetMol
    Your shopping cart is currently empty
Proceed to checkoutContinue shopping
TOPBioactivityChemical infoStorage&SolubilityCalculator

Alteplase

😃Good
Catalog No. TRP-00614Cas No. 105857-23-6

Alteplase (Actilyse; Activase) is a recombinant tissue plasminogen activator and serves as a thrombolytic agent, playing a crucial role in treating acute ischemic stroke, pulmonary embolism, acute myocardial infarction, and catheter occlusion. The specifications below refer to the active content of Alteplase, with the effective Alteplase content: total mass ratio = 1:46~1:50, with the actual ratio depending on the batch.

Alteplase
Other Forms of Alteplase:
tPA Protein, Mouse, Recombinant (His)TMPK-00810
In Stock
View details

Alteplase

😃Good
Catalog No. TRP-00614Cas No. 105857-23-6
Alteplase (Actilyse; Activase) is a recombinant tissue plasminogen activator and serves as a thrombolytic agent, playing a crucial role in treating acute ischemic stroke, pulmonary embolism, acute myocardial infarction, and catheter occlusion. The specifications below refer to the active content of Alteplase, with the effective Alteplase content: total mass ratio = 1:46~1:50, with the actual ratio depending on the batch.
Pack SizePriceUSA WarehouseGlobal WarehouseQuantity
10 mgInquiryInquiryInquiry
50 mgInquiryInquiryInquiry
Add to Quotation
In Stock Estimated shipping dateUSA Warehouse[1-2 days] Global Warehouse[5-7 days]
All TargetMol products are for research purposes only and cannot be used for human consumption. We do not provide products or services to individuals. Please comply with the intended use and do not use TargetMol products for any other purpose.
Questions
TargetMol
View More

Resource Download

Product Introduction

Bioactivity
Description
Alteplase (Actilyse; Activase) is a recombinant tissue plasminogen activator and serves as a thrombolytic agent, playing a crucial role in treating acute ischemic stroke, pulmonary embolism, acute myocardial infarction, and catheter occlusion. The specifications below refer to the active content of Alteplase, with the effective Alteplase content: total mass ratio = 1:46~1:50, with the actual ratio depending on the batch.
In vitro
Alteplase (8.3 and 250 μg/mL, 12 hours) significantly reduces activity in human fetal retinal pigment epithelial cells (hfRPE cells). Additionally, Alteplase (8.3 and 250 μg/mL, 0-6 hours) markedly decreases transepithelial resistance in a time-dependent manner and induces cell death in hfRPE cells. The product formulation includes excipients such as L-arginine, phosphate, and polysorbate 80.
In vivo
Administering Alteplase (0.9-10 mg/kg, intravenous injection, 20 to 40 minutes after onset or 180 and 240 minutes after onset) is beneficial when given early, within 3 hours of stroke onset, in mice that experienced thromboembolic stroke. However, if administration is delayed for 3 hours or more, it does not provide benefits.
Chemical Properties
Cas No.105857-23-6
Storage & Solubility Information
StoragePowder: -20°C for 3 years | In solvent: -80°C for 1 year

Calculator

  • Molarity Calculator
  • Dilution Calculator
  • Reconstitution Calculator
  • Molecular Weight Calculator

In Vivo Formulation Calculator (Clear solution)

Please enter your animal experiment information in the following box and click Calculate to obtain the stock solution preparation method and in vivo formula preparation method:
TargetMol | Animal experimentsFor example, your dosage is 10 mg/kg Each animal weighs 20 g, and the dosage volume is 100 μL . TargetMol | Animal experiments A total of 10 animals were administered, and the formula you used is 5% TargetMol | reagent DMSO+30% PEG300+5% Tween 80+60% Saline/PBS/ddH2O. So your working solution concentration is 2 mg/mL。
Stock solution preparation method: 2 mg of drug dissolved in 50 μL DMSOTargetMol | reagent (stock solution concentration of 40 mg/mL), if you need to configure a concentration that exceeds the solubility of the product, please contact us first.
Preparation method for in vivo formula: Take 50 μL DMSOTargetMol | reagent main solution, add 300 μLPEG300TargetMol | reagent mix well and clarify, then add 50 more μL Tween 80, mix well and clarify, then add 600 more μLSaline/PBS/ddH2OTargetMol | reagent mix well and clarify
The above example illustrates how to use "In Vivo Formulation Calculator" and does not represent a recommended formulation for any specific compound. Please select an appropriate dissolution method based on your experimental animals and route of administration.
All types of co-solvents required for the protocol, such asDMSO, PEG300/ PEG400, Tween 80, SBE-β-CD, corn oil are available for purchase on the TargetMol website with a simple click.
1 Enter information below:
mg/kg
g
μL
2 Enter the in vivo formulation:
% DMSO
%
% Tween 80
% Saline/PBS/ddH2O

Dose Conversion

You can also refer to dose conversion for different animals. More Dose Conversion

Tech Support

Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc
Related Tags: buy Alteplase | purchase Alteplase | Alteplase cost | order Alteplase | Alteplase in vivo | Alteplase in vitro
TargetMol | Logo

Copyright © 2015-2026 TargetMol Chemicals Inc. All Rights Reserved.